Literature DB >> 18096286

Increased serum levels of CCL11/eotaxin in schizophrenia.

Antonio Lucio Teixeira1, Helton Jose Reis, Rodrigo Nicolato, Gustavo Brito-Melo, Humberto Correa, Mauro Martins Teixeira, Marco Aurelio Romano-Silva.   

Abstract

BACKGROUND: Inflammatory and immune alterations occur and may be relevant in patients with schizophrenia. Chemokines are a subgroup of cytokines that play a major role in the recruitment of determined subsets of leukocytes into tissues. To date no study has evaluated whether levels of chemokines are altered in patients with schizophrenia.
OBJECTIVE: To evaluate serum levels of CC and CXC chemokines of schizophrenic patients and age- and gender-matched controls.
METHODS: Forty male institutionalized schizophrenic patients (mean+/-SD age, 52.3+/-9.9) and 20 asymptomatic matched controls were recruited for this study. Severity of symptoms was assessed using BPRS, PANSS and AIMS. All patients were under typical antipsychotic treatment. Serum concentrations of chemokines were measured by ELISA.
RESULTS: There was no statistical difference in serum levels of CCL2, CCL3, CCL24, CXCL9 and CXCL10 between controls and patients. Serum levels of CCL11 were increased in schizophrenic patients when compared to controls. Serum levels of chemokines were not correlated with the length of disease or hospitalization and the severity of involuntary movements, positive and/or negative symptoms.
CONCLUSION: CCL11 is a ligand for CCR3, a receptor expressed preferentially on Th2 lymphocytes, mast cells and eosinophils. Higher serum levels of CCL11 in schizophrenia reinforce the view that this disease may be associated with a Th1/Th2 imbalance with a shift toward a Th2 immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096286     DOI: 10.1016/j.pnpbp.2007.11.019

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  24 in total

1.  Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells.

Authors:  Michelle A Erickson; Yoichi Morofuji; Joshua B Owen; William A Banks
Journal:  J Pharmacol Exp Ther       Date:  2014-04-04       Impact factor: 4.030

2.  Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging.

Authors:  Leticia Sanguinetti Czepielewski; Raffael Massuda; Bruna Panizzutti; Lucas Kich Grun; Florencia María Barbé-Tuana; Antonio Lucio Teixeira; Deanna M Barch; Clarissa S Gama
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

3.  The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.

Authors:  Hussein Kadhem Al-Hakeim; Abbas F Almulla; Michael Maes
Journal:  Neurotox Res       Date:  2020-01-08       Impact factor: 3.911

4.  Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.

Authors:  Enrico Domenici; David R Willé; Federica Tozzi; Inga Prokopenko; Sam Miller; Astrid McKeown; Claire Brittain; Dan Rujescu; Ina Giegling; Christoph W Turck; Florian Holsboer; Edward T Bullmore; Lefkos Middleton; Emilio Merlo-Pich; Robert C Alexander; Pierandrea Muglia
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

5.  Abnormalities in chemokine levels in schizophrenia and their clinical correlates.

Authors:  Suzi Hong; Ellen E Lee; Averria Sirkin Martin; Benchawanna Soontornniyomkij; Virawudh Soontornniyomkij; Cristian L Achim; Chase Reuter; Michael R Irwin; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-09-17       Impact factor: 4.939

6.  Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis.

Authors:  E Fernandez-Egea; A Bruna; C Garcia-Rizo; M Bernardo; B Kirkpatrick
Journal:  Mol Psychiatry       Date:  2009-11       Impact factor: 15.992

Review 7.  Cytokines and myelination in the central nervous system.

Authors:  Thomas Schmitz; Li-Jin Chew
Journal:  ScientificWorldJournal       Date:  2008-11-02

8.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

9.  Change in plasma cytokine levels during risperidone treatment in children with autism.

Authors:  Jae Eun Choi; Felicia Widjaja; Milo Careaga; Stephen Bent; Paul Ashwood; Robert L Hendren
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-12       Impact factor: 2.576

10.  Increased interictal serum levels of CXCL8/IL-8 and CCL3/MIP-1α in migraine.

Authors:  Halina Duarte; Antonio L Teixeira; Natália P Rocha; Renan B Domingues
Journal:  Neurol Sci       Date:  2014-09-06       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.